Inflammaging & Longevity: How Chronic Low-Grade Inflammation Silently Accelerates Aging

Table of Contents

• What Is Inflammaging — and Why It’s Different from Acute Inflammation
• NF-κB and the NLRP3 Inflammasome — The Molecular Drivers
• The Primary Sources of Inflammaging
• Inflammaging and Major Age-Related Diseases
• Evidence-Based Anti-Inflammaging Interventions
• The Clinical Connection — Inflammation and Foot & Ankle Conditions
• Frequently Asked Questions

In 2000, Italian immunologist Claudio Franceschi and colleagues published a paper in Annals of the New York Academy of Sciences coining a term that has since become one of the most cited concepts in aging biology: inflammaging — the persistent, low-grade, systemic inflammation that emerges with aging and appears to be mechanistically upstream of virtually every major chronic disease of later life. Unlike the acute inflammation you experience with an infection or injury — which is intense, localized, and self-limiting — inflammaging is a slow background hum: C-reactive protein at 3–5 mg/L rather than 100+ mg/L, IL-6 at 3–5 pg/mL rather than 50–100 pg/mL. Below the threshold of clinical diagnosis, above the threshold of biological silence — and relentlessly corrosive over decades.

What makes inflammaging clinically important is the mounting evidence that these seemingly modest inflammatory elevations predict outcomes with frightening accuracy. A 2013 meta-analysis of 160,309 adults in the European Heart Journal found that CRP in the top versus bottom tertile was associated with a 45% higher risk of cardiovascular events — independently of lipid levels, blood pressure, and smoking. IL-6 elevations in midlife predict Alzheimer’s disease development 10–20 years later (Engelhart et al., Neurology, 2004). TNF-α drives insulin resistance and sarcopenia independently of other metabolic factors. In my functional medicine practice, measuring a high-sensitivity CRP, IL-6, and sometimes TNF-α in every patient over 45 has become as standard as measuring a lipid panel — because the inflammation picture is often more predictive of long-term trajectory than the cholesterol numbers everyone obsesses over.

What Is Inflammaging — and Why It’s Different from Acute Inflammation

Acute inflammation is one of biology’s most elegantly designed systems. When tissue is damaged or pathogens invade, the innate immune system deploys a coordinated response: mast cells release histamine, platelets aggregate, neutrophils flood the site and release proteases and ROS to kill pathogens, macrophages arrive to clear debris, and resolution mediators (specialized pro-resolving mediators: lipoxins, resolvins, protectins) orchestrate the shutdown, restoring tissue to homeostasis within days to weeks. This process is essential for survival — without it, minor infections would be fatal.

Inflammaging shares the molecular machinery of acute inflammation but differs in its origin and trajectory. It is sterile (no pathogen triggers it), chronic (it doesn’t resolve), low-intensity (below the threshold of clinical symptoms), and systemic (circulating throughout the body rather than localized). Its sources are diverse and intersecting: accumulating senescent cells that leak pro-inflammatory cytokines into surrounding tissue; dysfunctional mitochondria generating ROS and activating the NLRP3 inflammasome; visceral adipose tissue acting as an endocrine organ secreting adipokines (leptin, resistin, IL-6); gut microbiome dysbiosis allowing lipopolysaccharide (LPS) from gram-negative bacteria to translocate across a permeable gut epithelium into systemic circulation; and unresolved psychological stress driving chronic HPA axis and sympathetic activation. These sources feed each other in positive feedback loops — visceral fat promotes dysbiosis, dysbiosis drives intestinal permeability, LPS translocation activates macrophages in fat tissue, driving more adipokine production — creating an age-accelerating inflammatory spiral.

The Inflammaging Biomarkers Worth Tracking

The most clinically validated inflammaging biomarkers — those with the strongest longitudinal evidence for predicting chronic disease and mortality — are:

• High-sensitivity CRP (hsCRP): Optimal <1.0 mg/L; concerning 1–3 mg/L; elevated risk >3 mg/L. Most accessible, widely available, reflects systemic IL-6 signaling (CRP is produced by the liver in response to IL-6). Best measured fasting, in the absence of acute illness.
• IL-6: A direct inflammaging mediator. Optimal <2 pg/mL; levels above 3–5 pg/mL in midlife are associated with significantly accelerated cognitive and cardiovascular aging. Not routinely measured but available through functional medicine panels.
• Fibrinogen: A coagulation factor elevated by inflammation; predicts cardiovascular and cerebrovascular risk. Optimal 200–300 mg/dL.
• TNF-α: A master pro-inflammatory cytokine that drives NF-κB and promotes insulin resistance, sarcopenia, and endothelial dysfunction. Measurable in research and some functional medicine panels.
• GlycA (glycoprotein acetyls): An NMR-measured composite marker of inflammation that integrates multiple acute-phase proteins; emerging evidence suggests it may be more predictive than hsCRP for cardiometabolic risk.

NF-κB and the NLRP3 Inflammasome — The Molecular Drivers

The master transcription factor coordinating inflammaging gene expression is NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells). In unstimulated cells, NF-κB is sequestered in the cytoplasm by its inhibitor, IκB. When activated by any of dozens of upstream signals — LPS, TNF-α, reactive oxygen species, AGEs (advanced glycation end-products), saturated fatty acids, IL-1β — IκB is phosphorylated and degraded, freeing NF-κB to translocate to the nucleus and drive expression of a battery of pro-inflammatory genes: cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), IL-6, IL-1β, TNF-α, and matrix metalloproteinases (MMPs). The result is an amplifying transcriptional program that, in the context of acute infection, orchestrates a powerful immune response — but in the context of chronic low-level activation, produces the steady-state inflammatory tone of inflammaging.

The NLRP3 inflammasome is a cytosolic multiprotein complex that acts as a danger sensor — activating in response to crystalline particles (urate, cholesterol crystals, silica), mitochondrial ROS, ATP released from damaged cells, and lysosomal rupture. When activated, NLRP3 recruits the adapter protein ASC and caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their active forms — among the most potent inflammatory mediators known. Constitutive low-level NLRP3 activation by the chronic stimuli of aging (elevated circulating urate, cholesterol crystals in atherosclerotic plaques, mitochondrial ROS from dysfunctional organelles, AGEs from decades of glycation) is now recognized as a primary driver of the gout-related, atherosclerotic, and neurodegenerative manifestations of inflammaging. Notably, several candidate longevity drugs — including quercetin, fisetin, and canakinumab (an anti-IL-1β antibody) — target this pathway specifically.

The Primary Sources of Inflammaging

Senescent Cells and the SASP

Cellular senescence — the permanent cell cycle arrest that occurs in response to replicative exhaustion (telomere shortening), DNA damage, or oncogenic stress — is one of the primary sources of inflammaging in aging tissues. Senescent cells do not die; they persist, resist apoptosis, and secrete a complex mixture of pro-inflammatory cytokines, chemokines, proteases, and growth factors collectively termed the Senescence-Associated Secretory Phenotype (SASP). SASP components include IL-6, IL-8, IL-1α, MMP-3, MMP-9, and plasminogen activator inhibitor-1 — a pro-inflammatory cocktail that creates a chronically inflamed local microenvironment, promotes neighboring cell senescence (paracrine senescence spread), degrades extracellular matrix, and attracts immune cells that are themselves impaired in clearing senescent cells with age. As senescent cell burden accumulates throughout the body — estimated to represent 5–15% of cells in some aging tissues — the aggregate SASP output contributes meaningfully to the systemic inflammatory tone of inflammaging.

Visceral Adipose Tissue as an Inflammatory Organ

Visceral adipose tissue (VAT) — the metabolically active fat depot surrounding the abdominal organs, quantifiable by waist circumference, waist-to-hip ratio, or imaging — is not metabolically inert. It is an endocrine organ that, when expanded, secretes large quantities of pro-inflammatory adipokines: leptin (which drives macrophage activation and T-cell proliferation), resistin (which impairs insulin signaling and promotes NF-κB activation), and directly IL-6 and TNF-α from resident adipose macrophages (termed crown-like structures when surrounding lipid-engorged hypertrophic adipocytes). A 2019 analysis in Nature Reviews Endocrinology found that VAT-derived IL-6 accounts for approximately 15–35% of circulating IL-6 in individuals with metabolic syndrome — making fat loss from the visceral depot one of the most direct anti-inflammaging interventions available. Notably, VAT responds dramatically to aerobic exercise (which preferentially reduces visceral fat over subcutaneous fat) and caloric restriction, even before significant changes in total body weight occur.

Inflammaging and Major Age-Related Diseases

Cardiovascular Disease — Atherosclerosis as Inflammatory Disease

The Ridker et al. JUPITER trial (2008, New England Journal of Medicine) provided landmark evidence that inflammation, independent of LDL cholesterol, drives cardiovascular events. In this trial of 17,802 healthy adults with normal LDL but elevated hsCRP (>2 mg/L), rosuvastatin treatment — which reduces CRP by 37% in addition to its LDL effects — reduced cardiovascular events by 44% compared to placebo. The CANTOS trial (2017, NEJM) then tested the direct anti-inflammatory hypothesis: canakinumab, an IL-1β antibody with no lipid-lowering effects, reduced recurrent cardiovascular events by 15% in post-MI patients with elevated CRP — the first proof-of-concept that targeting inflammation directly (without touching lipids) prevents heart attacks. Atherosclerosis is now understood to be fundamentally an inflammatory disease: LDL oxidation in the arterial intima activates macrophages (foam cells), which release MMPs that weaken plaque fibrous caps, creating the rupture-prone plaques responsible for most fatal MIs.

Neurodegeneration — The Neuroinflammation Connection

In the brain, inflammaging manifests as neuroinflammation — chronic activation of the brain’s resident immune cells, microglia, that transitions from their normal neuroprotective surveillance role to a chronically activated state driving synaptic pruning, neuronal death, and amyloid-β clearance failure. A 2005 paper by Akiyama and colleagues in the Neurobiology of Aging documented the extent of microglial activation in Alzheimer’s disease brains and its correlation with cognitive decline. More recent work by Bhatt et al. (2021) established that peripheral inflammaging markers — specifically elevated CRP and IL-6 at age 50 — predicted hippocampal volume loss and cognitive function decline 20 years later in the Whitehall II cohort. The inflammasome-derived IL-1β and IL-18 are particularly neurotoxic, triggering caspase-1-mediated pyroptosis in neurons and promoting tau hyperphosphorylation — a central pathological feature of Alzheimer’s disease.

Sarcopenia — Inflammation-Driven Muscle Loss

TNF-α and IL-6 — two central inflammaging mediators — directly suppress muscle protein synthesis by activating NF-κB in muscle cells, which in turn activates the ubiquitin-proteasome pathway (the cellular machinery for protein degradation). The result is a negative nitrogen balance that accelerates sarcopenia beyond what mechanical disuse or protein insufficiency alone would produce. This creates a bidirectional inflammatory-sarcopenic vicious cycle: inflammaging drives muscle catabolism, and declining muscle mass reduces the body’s capacity to produce anti-inflammatory myokines (IL-6 from contracting muscle in acute exercise is actually anti-inflammatory in the short term; irisin, meteorin-like, BDNF from muscle all have systemic anti-inflammatory actions). A 2012 meta-analysis in Ageing Research Reviews found that elevated IL-6 was among the strongest predictors of accelerated sarcopenic muscle loss in community-dwelling older adults, with each standard deviation increase in IL-6 associated with approximately 40% faster annual decline in appendicular lean mass.

Evidence-Based Anti-Inflammaging Interventions

Exercise — The Most Potent Anti-Inflammatory Tool

Regular physical activity is the most consistently anti-inflammatory lifestyle intervention across all population studies, with an effect size comparable to or exceeding any single pharmacological anti-inflammatory agent. The mechanisms are multiple and complementary: acute exercise produces an IL-6 burst from contracting muscle that triggers downstream IL-10 and IL-1Ra (anti-inflammatory interleukins) release, actively suppressing TNF-α and NF-κB activity in the post-exercise period; regular exercise reduces visceral adipose tissue (the primary inflammatory adipokine source); exercise activates PGC-1α in muscle, which directly inhibits NF-κB transcription; and exercise promotes muscle mass, increasing myokine output and reducing the muscle loss that drives secondary inflammatory cascades. A 2019 Cochrane review found that aerobic exercise training significantly reduced hsCRP (weighted mean difference -0.64 mg/L), IL-6 (-1.01 pg/mL), and TNF-α (-0.34 pg/mL) across 69 trials. Both aerobic and resistance training produce anti-inflammatory effects, with combination programs appearing superior to either modality alone.

Diet — Mediterranean Eating as Anti-Inflammatory Architecture

The Mediterranean dietary pattern — high in olive oil (oleocanthal, a natural COX-2 inhibitor), polyphenols (quercetin, resveratrol, hydroxytyrosol activating SIRT1 and suppressing NF-κB), omega-3 fatty acids (EPA/DHA as substrates for resolving mediators that actively resolve inflammation), and fiber (supporting anti-inflammatory short-chain fatty acid production) — is one of the most extensively validated anti-inflammaging dietary patterns. The PREDIMED trial found significantly lower CRP and IL-6 in the Mediterranean diet arms versus low-fat control after 5 years. A 2018 meta-analysis of 18 trials found Mediterranean diet adherence associated with 26% lower CRP, 15% lower IL-6, and 18% lower TNF-α on average. Specific dietary anti-inflammatory strategies include: eliminating refined sugars and seed oils (which activate NLRP3 through AGE formation and lipid peroxidation), increasing omega-3 to omega-6 ratio (targeting 1:3 rather than the typical 1:15–20 Western diet ratio), and maximizing dietary polyphenol density through vegetables, fruits, olive oil, green tea, and spices.

Sleep — The Nightly Anti-Inflammatory Reset

Inadequate sleep (below 7 hours per night) is one of the most powerful drivers of acute and chronic CRP elevation. A meta-analysis by Irwin and colleagues (2016, Biological Psychiatry) found that sleep disturbance was associated with a 150% increase in the odds of elevated CRP and a 40% increase in IL-6 — effects that rivaled chronic disease and adiposity as CRP predictors. The mechanism involves HPA axis dysregulation (cortisol increases NF-κB activity), sympathetic nervous system activation (norepinephrine-driven inflammatory signaling), and impaired glymphatic clearance of inflammatory debris from the brain. For patients focused on reducing inflammaging, sleep optimization is arguably as important as diet and exercise — and more rapidly acting: a single week of restricted sleep to 6 hours produces measurable NF-κB activation in peripheral blood mononuclear cells (Irwin et al., 2008).

Targeted Supplements with Anti-Inflammaging Evidence

Several compounds have mechanistic and clinical evidence for reducing inflammaging biomarkers:

• Omega-3 fatty acids (EPA/DHA): 2–4 g/day reduces CRP by 20–30% in multiple RCTs; EPA and DHA are substrates for resolvins and protectins — the specialized pro-resolving mediators that actively switch off NF-κB and facilitate inflammatory resolution rather than just suppression.
• Quercetin and Fisetin: Flavonoid senolytics/senomorphics that suppress NF-κB, inhibit NLRP3 inflammasome activation, and selectively clear senescent cells in animal models; emerging human data (Kirkland 2020, EBioMedicine) shows reduced senescent cell burden after pulsed dosing (quercetin 500 mg + dasatinib for 3 days).
• Curcumin (as liposomal or phosphatidylcholine-bound formulations): Direct NF-κB and COX-2 inhibitor; a 2016 meta-analysis found bioavailable curcumin formulations reduced CRP by 0.64 mg/L and MDA (oxidative stress marker) significantly vs placebo — with poor bioavailability being the primary reason earlier trials failed.
• Resveratrol: SIRT1 activator that deacetylates and inactivates the p65 subunit of NF-κB; clinical evidence is modest but mechanistic rationale remains strong, particularly when combined with NAD+ precursors.

The Clinical Connection — Inflammation and Foot & Ankle Conditions

Virtually every foot and ankle condition I treat in adults over 50 has an inflammaging component — not always as the primary cause, but consistently as a driver of chronicity and slow recovery. Understanding this connection changes how I approach treatment: addressing the systemic inflammatory background is not optional maintenance for otherwise healthy individuals; it is clinically necessary for patients whose conditions fail to resolve despite technically adequate mechanical treatment.

Plantar Fasciitis — The Inflammaging Foot Condition

Plantar fasciitis is most accurately described as plantar fasciosis — a degenerative condition rather than a pure acute inflammatory one — but it exists on a tissue substrate that is profoundly shaped by systemic inflammaging. The plantar fascia’s collagen architecture degenerates with age and chronic mechanical loading, but the rate and severity of this degeneration is amplified by TNF-α (which upregulates MMPs that degrade collagen matrix), IL-6 (which impairs fibroblast synthetic function), and AGEs (which crosslink collagen fibers, reducing tensile flexibility and increasing susceptibility to microtears). In patients with metabolic syndrome — where all three of these inflammatory mediators are chronically elevated — plantar fasciitis recurs earlier, resolves slower, and fails conservative treatment at higher rates. My most treatment-resistant plantar fasciitis patients are almost uniformly those with visceral obesity, elevated CRP, and diets heavy in refined carbohydrates. When we address the systemic inflammatory load alongside mechanical offloading, cortisol injections, and physical therapy, outcomes improve substantially.

Peripheral Arterial Disease and Wound Healing

Peripheral arterial disease is an atherosclerotic condition — and as the JUPITER and CANTOS trials established, atherosclerosis is at its core an inflammatory disease. Elevated CRP and IL-6 are independent predictors of PAD progression, and PAD patients with elevated inflammatory markers have significantly worse limb salvage outcomes following revascularization. For patients with diabetic foot ulcers — the convergence of neuropathy, ischemia, immune impairment, and elevated inflammation — the systemic inflammaging context is the field in which every wound heals (or doesn’t). Neutrophil dysfunction in the diabetic inflammatory milieu — characterized by paradoxical chronic low-grade activation alongside impaired acute-response killing capacity — creates wounds that are simultaneously too inflamed (unable to transition to proliferative repair) and under-defended (impaired bacterial clearance). Restoring the anti-inflammatory/pro-resolution balance through omega-3 supplementation, dietary intervention, and exercise-based rehabilitation is part of my comprehensive approach to diabetic wound management alongside the standard wound care protocols.

Achilles Tendinopathy and Gut Microbiome

Emerging research has connected gut dysbiosis — one of the primary drivers of inflammaging via LPS translocation — with increased rates of tendon pathology. A 2019 study in Annals of the Rheumatic Diseases found that patients with Achilles tendinopathy showed significantly different gut microbiome profiles compared to healthy controls, with reduced abundance of anti-inflammatory Faecalibacterium prausnitzii and Akkermansia muciniphila, and increased representation of LPS-producing Proteobacteria. The proposed mechanism: gut-derived LPS activates Toll-like receptor 4 (TLR4) in tendon tissue, driving local NF-κB activation and collagen-degrading MMP expression. Whether gut microbiome intervention can improve tendon outcomes in humans remains under investigation — but the mechanistic link is compelling and consistent with the broader inflammaging framework.

Frequently Asked Questions

How do I know if I have elevated inflammaging?

The most accessible test is high-sensitivity CRP (hsCRP), available through standard blood panels. Optimal is below 1.0 mg/L; levels of 1–3 mg/L represent “average” cardiovascular risk; above 3 mg/L signals elevated inflammaging. Always confirm that the elevated CRP is not due to an acute illness (cold, dental work, injury) — CRP should be measured when you are well. Additional markers worth requesting from a functional medicine physician: IL-6, fibrinogen, ferritin (often elevated with chronic inflammation), uric acid (NLRP3 activator), and a fasting insulin (insulin resistance is both a driver and consequence of inflammaging).

Can inflammaging be reversed?

Substantially, yes — though “reversing” may be a better description than “eliminating.” Multiple intervention studies have demonstrated that comprehensive lifestyle modification (Mediterranean diet + regular exercise + sleep optimization + stress reduction) can reduce hsCRP by 30–50% over 6–12 months. Visceral fat loss of 5–10% of body weight produces disproportionate improvements in inflammatory biomarkers. Aggressive management of gut dysbiosis (through dietary fiber, fermented foods, targeted probiotic intervention) can measurably reduce LPS-driven inflammatory activation. The centenarians with the best health trajectories are not inflammation-free — they appear to have more robust resolution mechanisms (higher omega-3 status, more active anti-inflammatory myokine production from maintained muscle mass) that counter pro-inflammatory signals more effectively. Optimizing resolution capacity, not just suppressing inflammation, is the goal.

Do NSAIDs treat inflammaging?

NSAIDs (ibuprofen, naproxen, aspirin) inhibit COX-1 and COX-2 enzymes that produce prostaglandins — acutely reducing inflammation and pain but not addressing the upstream drivers of inflammaging. More concerningly, NSAIDs also inhibit the production of SPMs (specialized pro-resolving mediators) that derive from the same arachidonic acid pathway, potentially impairing the resolution phase of inflammation. Chronic NSAID use is associated with gut permeability damage (contributing to LPS translocation), renal prostaglandin impairment, and cardiovascular risk with prolonged use. Low-dose aspirin (81 mg/day) has anti-inflammatory effects through COX-1 acetylation that generates 15-epi-lipoxin A4 (a resolution mediator), but the ARRIVE trial found no benefit from aspirin in primary prevention in adults without prior cardiovascular events. NSAIDs are appropriate for acute pain management — they are not an appropriate strategy for addressing chronic inflammaging.

What foods are most pro-inflammatory?

The most pro-inflammaging dietary elements, in order of evidence strength: refined sugars and high-fructose corn syrup (activate NLRP3 through uric acid and AGE formation, drive visceral fat accumulation); industrial seed oils high in omega-6 linoleic acid (sunflower, safflower, corn, soybean oils — increase omega-6/omega-3 ratio and provide substrates for pro-inflammatory eicosanoids); ultra-processed foods (dietary pattern associated with the highest inflammatory biomarker burden in epidemiological studies); trans fats (now largely banned in the US but still present in some imported products — directly activate NF-κB in endothelial cells); and red meat in excess (specifically processed red meat — nitrites, AGEs from high-temperature cooking, heme iron at high doses). Whole food animal proteins and unprocessed red meat consumed in the context of an overall plant-rich diet do not show consistent pro-inflammatory effects in well-controlled studies.

Key References

• Franceschi C, et al. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. Annals of the New York Academy of Sciences. 2000;908:244-254. PMID: 10911963
• Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER). New England Journal of Medicine. 2008;359(21):2195-2207. PMID: 18997196
• Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). New England Journal of Medicine. 2017;377(12):1119-1131. PMID: 28845751
• Engelhart MJ, et al. Inflammatory Proteins in Plasma and the Risk of Dementia. Archives of Neurology. 2004;61(5):668-672. PMID: 15148142
• Irwin MR, et al. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis. Biological Psychiatry. 2016;80(1):40-52. PMID: 26140821
• Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and ‘Garb-aging’. Trends in Endocrinology and Metabolism. 2017;28(3):199-212. PMID: 28081895

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Zone 2 Training & Longevity
• Optimal Protein Intake for Longevity
• Gut Microbiome: Butyrate, Akkermansia, Longevity
• Sleep & Longevity: Glymphatic System